INTERPRETATION AND ESTIMATION OF CONDITIONAL POWER IN INTERIM ANALYSES OF CLINICAL TRIALS: OFTEN IGNORED IN DECISION MAKING PROCESS

Author:

Marimuthu S.1,Thenmozhi Mani2,Joy Melvin3,Babu Malavika4,David Sudarsanam Thambu5,Jeyaseelan L.6

Affiliation:

1. M.Sc., Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India

2. Ph.D., Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.

3. M.Sc., TRCI, Faculty of Medical Sciences, Newcastle University, UK.

4. M.Sc., Centre for Trials Research, College of Biomedical and Life Science, Cardiff University.

5. MD Dip.NB., Department of Medicine, and Clinical Epidemiology Unit, Christian Medical College, Vellore, Tamil Nadu, India.

6. Ph.D., Department of Basic Sciences, MBR University of Medicine and Health Sciences, Dubai, UAE.

Abstract

In group sequential trials, the interim results are more promising in the early termination of a trial either for efcacy or futility of the trial. This reduces the cost and time implications. Moreover, interim analyses play a key role to tackle the problem that arises due to adverse effects. In concern with the early stopping of trials, there are numerous stopping methods among them the Conditional power (CP) approach is best recommended. The CP approach provides the probability of getting signicant results at the end of the study given the data observed so far. There are very few Indian studies that had incorporated the concept of CP and made decisions based on the results. This study popularises the CP approach detailing computing and its interpretation and is thereby facilitating clinical researchers to use this approach effectively. We have used real-time and hypothetical examples and illustrated the concept of CP under trend, CP under null, and CP under design. We suggest stopping the study for efcacy when the CP under null is greater than 80% and stopping the study for futility when CP under trend is less than 30%.

Publisher

World Wide Journals

Subject

General Medicine,Organic Chemistry,Drug Discovery,Pharmacology,General Medicine,Law,Demography,Geochemistry and Petrology,Cell Biology,Genetics,Molecular Biology,Applied Microbiology and Biotechnology,Molecular Medicine,Immunology,Microbiology,Agricultural and Biological Sciences (miscellaneous),Anatomy,Physical and Theoretical Chemistry,Biomedical Engineering,Medicine (miscellaneous),Bioengineering,General Neuroscience,Nutrition and Dietetics,Medicine (miscellaneous),Pharmacology,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3